 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pyxis Oncology announces appointment of Kobayashi as CMO...

Pyxis Oncology announces appointment of Kobayashi as CMO

Dr. Kobayashi brings over 25 years of experience in oncology drug development, including Antibody Drug Conjugates (ADCs) and other oncology modalitiesBOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Pyxis...

Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that it has commenced an investigation of NAPCO Security Technologies Inc. (NASDAQ: PYXS) concerning possible breaches of...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of NAPCO Security Technologies Inc. (NASDAQ: PYXS)

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Pyxis Oncology (PYXS Research Report). The company's shar...

LifeSci Capital Reaffirms Their Buy Rating on Pyxis Oncology (PYXS)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Pyxis Oncology reports Q3 EPS (56c), consensus (51c)

PYX-201 (a novel first-in-concept and first-in-class tumor stroma targeting antibody-drug conjugate [ADC] product candidate) Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg; data...

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ: PYXS) concerning possible breaches of fiduciary duty...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ: PYXS)

Inspiring the Next Generation of Entrepreneurs at the Diversity and Equity Accelerator through Learning for Startups (DEALS) Workshop Inspiring the Next Generation of Entrepreneurs at the Diversity...

Inspiring the Next Generation of Entrepreneurs at the Diversity and Equity Accelerator through Learning for Startups (DEALS) Workshop

New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review PR Newswire...

New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers...

Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.

Watchers	2,318
52-Wk Low	$1.10
52-Wk High	$6.92

Market Cap	$78.4M
Volume (M)	279,370.00
52-Wk High	$6.92
52-Wk Low	$1.10

PYXS Pyxis Oncology Inc

About

Feed

News

Earnings

Fundamentals